115 related articles for article (PubMed ID: 38760614)
1. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
3. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma.
Cheng D; Zhao W; Chen R; Li D; Tang S; Fang C; Ji M
World J Surg Oncol; 2023 Feb; 21(1):33. PubMed ID: 36737768
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
6. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.
Zhang Y; Li H; Yu B; Sun S; Hu Z; Wu X; Zhang Y; Li B; Zhang Y; Xiang J; Wang J; Yu H
Thorac Cancer; 2024 May; 15(13):1072-1081. PubMed ID: 38532546
[TBL] [Abstract][Full Text] [Related]
8. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
10. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
11. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
12. Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?
Liu J; Zhu L; Huang X; Lu Z; Wang Y; Yang Y; Ye J; Gu C; Lv W; Zhang C; Hu J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):161. PubMed ID: 38536527
[TBL] [Abstract][Full Text] [Related]
13. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study.
Hong Z; Xu J; Chen Z; Xu H; Huang Z; Weng K; Cai J; Ke S; Chen S; Xie J; Duan H; Kang M
Int J Surg; 2023 Aug; 109(8):2168-2178. PubMed ID: 37318861
[TBL] [Abstract][Full Text] [Related]
14. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (CY-NICE).
Chen Y; Ren M; Li B; Meng Y; Wang C; Jiang P; Song T; Yang J; Zhu D; Yu Q
J Thorac Dis; 2023 Dec; 15(12):6761-6775. PubMed ID: 38249875
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Xu J; Cai Y; Hong Z; Duan H; Ke S
Int J Surg; 2024 Jan; 110(1):490-506. PubMed ID: 37800587
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
[TBL] [Abstract][Full Text] [Related]
20. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
Leng XF; Daiko H; Han YT; Mao YS
Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]